Stanoplex is prescribed for chronic infections, for conditions such as extensive surgery, [corticosteroid-induced myopathy, decubitus ulcers, burns] , or severe trauma, which require reversal of catabolic processes or protein-sparing effects. This is used in addition to, and not as replacements for, conventional treatment of these disorders.
Stanoplex is effective in raising hemoglobin concentrations in some cases of aplastic anemia (congenital or idiopathic).
Stanoplex is indicated in the prophylaxis of hereditary angioedema to decrease the frequency and severity of attacks.
Stanoplex is used in the treatment of hereditary angioedema.
Stanoplex is indicated in the treatment of conditions associated with decreased fibrinolytic activity due to antithrombin III deficiency or excess fibrinogen. These conditions may include cutaneous vasculitis, scleroderma of Raynaud’s disease, vasculitis of Behcet’s disease, and complications of deep vein thrombosis such as venous lipodermatosclerosis. Stanozolol is indicated in the prevention of recurrent venous thrombosis associated with antithrombin III deficiency. Stanozolol may be of benefit in patients susceptible to or with a history of thromboembolism for the treatment of vascular disorders associated with these forms of reduced fibrinolytic activity.
The new Stanoplex 10 formula is white tablet coated in a yellow protective cover that will prevent absorption in the stomach, thus allowing for correct absorption in the lower intestine.